- Conditions
- Ovarian Cancer
- Interventions
- INCB123667, Investigator's choice of chemotherapy
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 63
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Duarte, California + 56 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 1,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anxiety, Depressive Symptoms, Sleep Disturbance, Recurrent Disease, Fatigue, Quality of Life, Cancer
- Interventions
- Severe Anxiety/depression: High Intensity Stepped Care, Moderate Anxiety/depression: Low Intensity Stepped care, Enhanced Usual Care Control
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 166
- States / cities
- Fort Smith, Arkansas • Fresno, California • Modesto, California + 129 more
- Conditions
- Non-radiographic Spondyloarthritis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 52 more
- Conditions
- Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
- Interventions
- MEDI4736, MEDI4736 + Tremelimumab, Standard of Care
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 96 Years
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Fullerton, California • Los Angeles, California + 18 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, PF-06700841 15 mg, PF-06700841 30 mg, PF-06700841 45 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Fullerton, California • La Palma, California + 34 more
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Interventions
- TORL-2-307-MAB
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Fullerton, California • Los Angeles, California • Torrance, California + 2 more
- Conditions
- Dry Eye
- Interventions
- Systane Free
- Drug
- Lead sponsor
- Southern California College of Optometry at Marshall B. Ketchum University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Acute Ischaemic Stroke, Transient Ischaemic Attack
- Interventions
- ticagrelor, Acetylsalicylic acid (ASA)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 13,307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 115
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more
- Conditions
- Rhematoid Arthritis
- Interventions
- Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 60
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
- Conditions
- Secondary Hyperparathyroidism, End Stage Kidney Disease
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 50
- States / cities
- Anaheim, California • Chula Vista, California • Escondido, California + 43 more
- Conditions
- Solid Tumor
- Interventions
- Talazoparib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 19
- States / cities
- Bakersfield, California • Burbank, California • Fullerton, California + 10 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Biological · Procedure
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Fluticasone Propionate/Formoterol Fumarate, Formoterol Fumarate, Placebo
- Drug
- Lead sponsor
- Dey
- Industry
- Eligibility
- 40 Days and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Fullerton, California • San Diego, California + 20 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Dexlansoprazole MR
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 181
- States / cities
- Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 178 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
- Interventions
- furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
- Drug
- Lead sponsor
- ArriVent BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 69
- States / cities
- Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive, HER2, Estrogen Receptor Positive, ER, Triple Negative
- Interventions
- Lucitanib
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 33
- States / cities
- Sedona, Arizona • Bakersfield, California • Fullerton, California + 25 more
- Conditions
- Post COVID-19 Cognitive Impairment
- Interventions
- Vielight Neuro RX Gamma active device, Vielight Neuro RX Gamma sham device
- Device
- Lead sponsor
- Vielight Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Tanezumab, placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 48
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Baxdrostat/dapagliflozin, Dapagliflozin in combination with placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 114
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Surprise, Arizona + 97 more
- Conditions
- Macular Edema Secondary to Retinal Vein Occlusion
- Interventions
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
- Drug · Diagnostic Test
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 53
- States / cities
- Fullerton, California • Long Beach, California • Mountain View, California + 48 more
- Conditions
- Ovarian Neoplasms
- Interventions
- AMG 479, AMG 479 Placebo
- Drug
- Lead sponsor
- Translational Research in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 23
- States / cities
- Alhambra, California • Burbank, California • Fullerton, California + 17 more
- Conditions
- Periodontitis (Stage 3)
- Interventions
- Emanate Perio PODS
- Device
- Lead sponsor
- McGuire Institute
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Fullerton, California • New London, Connecticut • Boston, Massachusetts + 5 more
- Conditions
- Liver Neoplasms, Primary Liver Cancer, Secondary Liver Cancer, Tumor Liver, Benign Liver Tumor
- Interventions
- HistoSonics Edison System
- Device
- Lead sponsor
- HistoSonics, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 33
- States / cities
- Fullerton, California • Los Angeles, California • Mission Viejo, California + 26 more